AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02086942
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
Trial: NCT02096666
Drug: AMG 337
RxNorm normalized name: AMG-337
DrugBank: AMG-337 (DB15639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
Trial: NCT01120314
Drug: OTAMIXABAN (XRP0673)
RxNorm normalized name: Otamixaban
DrugBank: Otamixaban (DB06635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: solution for injection~Route: intravenous
Trial: NCT04326036
Drug: Sterile Normal Saline for Intravenous Use
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
Trial: NCT00678535
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT00678535
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT01537081
Drug: Mucinex
RxNorm normalized name: Mucinex
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
Trial: NCT01537081
Drug: Immediate-release Guaifenesin
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
Trial: NCT01192503
Drug: rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
Trial: NCT00652184
Drug: valaciclovir
RxNorm normalized name: valaciclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active valaciclovir
Trial: NCT03666351
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg
Trial: NCT03666351
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan Potassium 50 mg
Trial: NCT03666351
Drug: Losartan and Amlodipine
RxNorm normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
Trial: NCT04316806
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
Trial: NCT03404908
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
Trial: NCT03404908
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Trial: NCT03404908
Drug: metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
Trial: NCT03404908
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Trial: NCT04266509
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 milligram (mg) tablet
Trial: NCT04266509
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg provided as two 300 mg capsules.
Trial: NCT01328041
Drug: dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg twice daily
Trial: NCT03283098
Drug: Etelcalcetide
RxNorm normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
Trial: NCT00001812
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00418431
Drug: Intravitreal injection of Bevacizumab
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
Trial: NCT02725112
Drug: Pregabalin ER
RxNorm normalized name: Pregabalin ER
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
Trial: NCT01739933
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
Trial: NCT01739933
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
Trial: NCT00611468
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.
Trial: NCT00611468
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.
Trial: NCT02688088
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT01842932
Drug: Phloroglucin
RxNorm normalized name: Phloroglucin
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication of colonoscopy
Trial: NCT01842932
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
DrugBank: Cimetropium (DB09271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication of colonoscopy
Trial: NCT00002839
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01839019
Drug: ODM-102
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose escalation
Trial: NCT00803348
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
Trial: NCT03905317
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
Trial: NCT03905317
Drug: concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Trial: NCT03356977
Drug: Crisaborole ointment 2%
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied BID
Trial: NCT04207918
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg, by intravenous infusion once a week in 4-6 weeks.
Trial: NCT04207918
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
Trial: NCT00798317
Drug: Ocriplasmin 125µg
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 125µg of ocriplasmin intravitreal injection
Trial: NCT02154048
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02154048
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416715
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00416715
Drug: calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01930890
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Trial: NCT04021173
Drug: Anfibatide
RxNorm normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Trial: NCT00003044
Drug: cisplatin-e therapeutic implant
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01024491
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dose of paroxetine 15mg for 12 weeks
Trial: NCT01024491
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active daily treatment with paroxetine 20 mg
Trial: NCT01649544
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00996281
Drug: Olmesartan medoxomil and hydrochlorothiazide
RxNorm normalized name: Olmesartan Medoxomil and Hydrochlorothiazide Tablets
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet.
Trial: NCT01098877
Drug: PF-04634817 Placebo
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, placebo, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 1mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 3mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 10mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 30mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 100mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 300mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 600mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 900mg, single dose
Trial: NCT01098877
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, up to 900mg, single dose after food
Trial: NCT01098877
Drug: PF-04634817 Placebo
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, placebo, single dose after food
Trial: NCT01794741
Drug: Fluticasone propionate nasal spray
RxNorm normalized name: fluticasone propionate Metered Dose Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02699008
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antiplatelet agent
Trial: NCT02699008
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New P2Y12 receptor inhibitor antiplatelet agent
Trial: NCT04535713
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Trial: NCT04535713
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Trial: NCT04535713
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg i.v. on Day 1 beginnning Cycle 2+
Trial: NCT01437644
Drug: botulinum toxin intramuscular injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
Trial: NCT03054350
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daily oral dose
Trial: NCT02351687
Drug: Sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02351687
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01258153
Drug: Nepadutant oral solution
RxNorm normalized name: Nepadutant
DrugBank: Nepadutant (DB12538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily for 7 days
Trial: NCT01258153
Drug: Placebo matching Nepadutant oral solution
DrugBank: Nepadutant (DB12538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily for 7 days
Trial: NCT00881153
Drug: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00867087
Drug: inotuzumab ozogamicin (CMC-544)
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Trial: NCT00867087
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Trial: NCT02088073
Drug: Sodium zirconium cyclosilicate
RxNorm normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate
Trial: NCT01023087
Drug: Polymyxin E (Colistin)
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
Trial: NCT00975819
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liquid dosing based on trough levels
Trial: NCT00016744
Drug: Sodium 4-Phenylbutyrate (4PBA)
RxNorm normalized name: 4-phenylbutyrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The standard oral adult dose is 20g/day (tablets) for 4 days.
Trial: NCT00016744
Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
RxNorm normalized name: Conjugated Estrogens
DrugBank: Flavone (DB07776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Trial: NCT03535662
Drug: Orvepitant
RxNorm normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03535662
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily dosing for 10 days
Trial: NCT00196586
Drug: pegylated interferon alpha 2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00196586
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00911092
Drug: Chemotherapy (Fluorouracil and Cisplatin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²
Trial: NCT02969590
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
Trial: NCT02969590
Drug: Estrogen and Progesterone Replacement
RxNorm normalized name: testosterone and estrogen
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Replace hormones exogenously to create an artificial cycle